Printers that can now print DNA

Latest articles

Cellino bags $80 million to autonomise stem cell therapy manufacturing

Leaps by Bayer leads $80m Series A to enable Cellino to significantly expand patient access to stem cell-based therapies. Cellino Biotech, Inc, an autonomous stem cell...

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

NURO embarks on funding round for neurotech communication system

World’s first multimodal neurotech operating system from NURO allows you to communicate using just your brain. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Cellino bags $80 million to autonomise stem cell therapy manufacturing

Leaps by Bayer leads $80m Series A to enable Cellino to significantly expand patient access to stem cell-based therapies. Cellino Biotech, Inc, an autonomous stem cell...

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

Click the globe for translations.

DNA Script obtains CE Mark for SYNTAX DNA printing platform.

DNA Script, a leader in Enzymatic DNA Synthesis (EDS), announced the CE marking of its SYNTAX System, the first EDS-powered benchtop DNA printer. With this marking, the SYNTAX System meets EU safety, health and environmental protection guidelines, and DNA Script will begin commercial sales of the SYNTAX System in European countries.

Longevity.Technology: Time to read the small print! Oligonucleotides – often called oligos – are short single strands of synthetic DNA or RNA made up of nucleic acids. Clearly DNA is important, but because they are small, oligos are the ideal starting point for many molecular and synthetic biological applications. Oligos are used in everything from genetic testing to forensic research and are also ideal in next-generation sequencing, which can deliver large amounts of genetic data in a short amount of time – vital for longevity research.

Founded in 2014, DNA Script is a life sciences tech company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, allowing this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers full control and autonomy.

“We can now deliver the SYNTAX System, with all the benefits of in-house DNA oligo synthesis, to European researchers,” said DNA Script co-founder and CEO Thomas Ybert. “By enabling rapid, on-site DNA production, the SYNTAX System accelerates lab workflows and helps scientists find answers faster.”

The CE marking covers the entire SYNTAX platform, which includes a benchtop DNA printer, reagents and consumables. The printer sets up in around 15 minutes and can synthesize as many as 96 DNA oligonucleotides up to 60 nucleotides in length, printing 20mers in about 6 hours for same-day results, and up to 60mers in about 13 hours, or overnight. Following synthesis, the SYNTAX System purifies, quantifies and normalises oligos for seamless integration into any research workflow. The software suite monitors system performance and reagent levels to help users manage DNA print runs, reagents and results.

“The SYNTAX System gives researchers same-day oligo synthesis capabilities, allowing them to continuously innovate without delivery bottlenecks,” said Ybert. “DNA oligos can be printed on-demand at record speed, giving labs complete control over their workflows.”

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Sugar-proof your health with the GLYLO weight loss and antiaging supplement

Move your New Year's resolution up a gear with GLYLO, a double-action supplement that can increase weight loss while also slowing aging. Choosing an effective...

Related articles

Cellino bags $80 million to autonomise stem cell therapy manufacturing

Leaps by Bayer leads $80m Series A to enable Cellino to significantly expand patient access to stem cell-based therapies. Cellino Biotech, Inc, an autonomous stem cell...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

Mental illness drug discovery company Neurai Life Sciences launches

AI will drive discovery of innovative small molecules and next generation therapies to treat mental health disorders. Wuhan, a bioceutical company focused on alternative plant-based...

StarkAge secures 2 million euros for senescence targeting therapy

Funding from Bpifrance's Deeptech program will drive development of company’s immunotherapy approach targeting cellular senescence in age-related disease. French biotech startup StarkAge Therapeutics today announced...

Genflow IPO “starts a new chapter” for longevity biotech

Company floats on London Stock Exchange and becomes Europe’s first publicly traded longevity biotech. Today, Genflow Biosciences became the first longevity biotech IPO of 2022...

    Subscribe to our newsletter